TGen and Mission3 Renew Strategic Relationship

Phoenix, AZ – August 10, 2007 – Mission3, Inc., a leading provider of product lifecycle management software specifically serving the Life Sciences industry, today announced the renewal of their strategic partnership with TD2, the drug development arm of the Translational Genomics Research Institute (TGen).

TD2 has fully deployed Mission3’s product lifecycle management suite of MissionFire and FastCrossing to help organize and manage its drug development process. The suite facilitates collaboration between TD2’s sponsors and investigators, allowing data and critical decisions to be managed in real time.

“I couldn’t be more pleased with our partnership,” said Debbie Snyder, Vice President of Operations at TD2. “Having implemented MissionFire and FastCrossing has allowed TD2 to streamline operations and have insight into critical data and milestones during the development process. By deploying Mission3’s product lifecycle management technology, TD2 is able to operate a system of competitive advantages that distinguishes us versus our competition.”

“Our relationship is unique and beneficial, as it has allowed Mission3 to gain access to critical real-world experience for product development and enhancements. The result of this collaboration allows us to bring to market substantially better solutions for product lifecycle management that are specifically tailored to the demanding needs to the life sciences industry. Our technology clearly changes the way that companies manage the drug development process. This relationship has been a win-win for all of us.” said Dirk Karsten Beth, President of Mission3.

More about Mission3’s product lifecycle management suite can be viewed at http://www.mission3.com.

About Mission3, Inc.
Mission3 is a leading provider of product lifecycle management software that specifically serves the unique needs of the life sciences industry. Its state-of-the-art on-demand software suite allows companies to manage projects and documents; comply with regulatory requirements; and submit applications in an automated, electronic, and regulatory compliant environment. Companies taking full advantage of Mission3’s industry-leading innovative product lifecycle management suite can simultaneously create an electronic submission while a project is underway, significantly reducing the time and cost needed to develop a product and submit it for regulatory approval.

About TD2
TD2 helps investigators from research institutions, biotech and pharmaceutical companies evaluate the efficacy of their drug candidate by using preclinical models, genomic tools and coordination of Phase I clinical trials at various clinical facilities, including Mayo Clinic Scottsdale, Scottsdale Healthcare, the Arizona Cancer Center, and U.S. Oncology. TD2 also provides central coordination of an international team of investigators who are conducting studies in patients with pancreatic cancer. Although initially focused in oncology, TD2 expects to expand its capabilities to other disease areas including neurological diseases and diabetes.

CONTACT INFORMATION:
Chris Joslin
Vice President of Operations
Mission3, Inc.
www.mission3.com
602-957-2150 ext. 508
cjoslin@mission3.com


Amy Erickson
Office of Communications
Translational Genomics Research Institute (TGen)
(602) 343-8522
aerickson@tgen.org